Over 500 injections have been evaluated in Qilu and Kelun every year...7 leading pharmaceutical companies to "get together" in 7 varieties

Medical Network, July 16 News On July 15, Shanghai Pharmaceuticals issued an announcement stating that its wholly-owned subsidiary, Shanghai Pharmaceutical Dongying, has been approved for the imitation of Parecoxib Sodium for injection, which has been submitted for production in four categories, and is deemed to have been reviewed; in Prior to this, Hainan Jinrui Pharmaceutical's irinotecan hydrochloride injection was approved as a supplementary application, becoming the fourth company after Hengrui, Qilu, and Huiyu
.
Since the beginning of this year, the consistency evaluation of injections has exploded
.
According to data from Meinenet, 114 injection varieties (517 product specifications) passed or deemed to have passed the consistency evaluation in the first half of this year
.
Among them, systemic anti-infective drugs accounted for the largest proportion, nearly 30%, and anti-tumor and immunomodulators, nervous system drugs, digestive system and metabolic drugs accounted for more than 10%; in terms of varieties, parecoxib sodium for injection , Ambroxol Hydrochloride Injection, Ceftriaxone Sodium for Injection, and other 7 varieties are the most popular, and 10 or more companies have reviewed them; from the perspective of enterprises, Qilu Pharmaceutical, Kelun Pharmaceutical, and Yangzijiang Pharmaceutical rank among the top three There are 21, 18, and 16 injections that have been reviewed
.

5700 Yi injections over assessment lift the market tide, four categories of the hottest
Chinese public medical institutions terminal of injection drug sales (Unit: 100 million) Source: Chinese terminal competition public sector as the country enters the normalization Jicai, drugs Consistency evaluation continues to accelerate, and the consistency evaluation of injections is increasing at an alarming rate
.
According to data from Mi Nei.
com, in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will have sales of terminal chemical injections exceeding 570 billion yuan, accounting for nearly 60% of the chemical medicine market.

.
In the first half of this year, 114 injection varieties (517 product regulations) passed or deemed to have passed the consistency evaluation, of which more than 70% were approved for supplementary applications
.
It is worth mentioning that starting from last year, the injection review began to have a "blowout", and the companies with early layout are gradually entering the harvest period.
A total of 78 injection products (216 product specifications) have been reviewed during 2017-2020
.
In the first half of 2021, the distribution of over-evaluated injection therapy fields (category) From the perspective of the therapeutic areas (category) of over-evaluated injections in the first half of 2021, systemic anti-infective drugs accounted for the largest proportion, nearly 30%; anti- tumor and immunomodulators , Nervous system drugs, digestive system and metabolic drugs, all accounted for more than 10%
.
According to data from Meinenet, the three major categories of systemic anti-infective drugs, anti-tumor and immunomodulators, digestive system and metabolic drugs are among the top three in the terminal market of China's public medical institutions in 2020, with sales exceeding 100 billion yuan; nervous system Drugs ranked sixth, with sales of more than 90 billion yuan
.

Pharmaceutical companies "get together" 7 major injection varieties, Qilu, Kelun, Yangtze River.
.
.
Leading the
injection varieties in the first half of 2021.
Source: Mynet.
com MED2.
0 Chinese Drug Evaluation Database.
Note: The treatment field is counted based on the status start date ( In terms of sub-categories, the 114 injections reviewed in the first half of the year involved 34 sub-categories
.
Among them, systemic antibacterial drugs are the most with 22; followed by antitumor drugs with 20
.
Judging from the company's review situation, Qilu Pharmaceutical, Kelun Pharmaceutical, and Yangzijiang Pharmaceutical rank in the top three, with 21, 18, and 16 injections that have been reviewed
.
It is worth noting that in the first half of the evaluation companies, many of them caught up with the "last train" before the centralized procurement and bid opening
.
In the first half of 2021, there were 10 or more injection varieties with over-evaluated companies.
From the perspective of over-evaluation, 7 varieties, including parecoxib sodium for injection, ambroxol hydrochloride injection, and ceftriaxone sodium for injection, were the most popular.
, 10 or more companies have reviewed
.
Except for doxofylline injection, the sales of the other six injections in China's public medical institutions will each exceed 2 billion yuan in 2020
.
In addition, dexmedetomidine hydrochloride injection has been reviewed by 9 companies; azithromycin for injection and pantoprazole sodium for injection have been reviewed by 7 companies; docetaxel injection, ropivacaine hydrochloride injection, Cefazolin sodium for injection has been reviewed by 6 companies; citrate coffee/phenanthrene/injection, linezolid glucose injection, decitabine for injection, gemcitabine hydrochloride for injection, and levofloxacin sodium chloride injection are all available Five companies have passed reviews
.
Among the injection products reviewed in the first half of this year, 60 were not reviewed by companies before, including 36 were exclusive reviews
.
Sales of parecoxib sodium for terminal injection in public medical institutions in China in recent years (unit: 100 million yuan) Source: China’s public medical institutions’ terminal competition pattern On July 15, Shanghai Pharmaceuticals announced that its wholly-owned subsidiary , Shanghai Pharmaceutical Dongying Parecoxib Sodium for Injection, which is produced in the imitation category 4, is approved and deemed to be over-reviewed
.
According to data from Meinenet, in 2020, the sales of parecoxib sodium for terminal injection in public medical institutions in China will exceed 2 billion yuan, and Pfizer has the largest market share
.
Up to now, there are close to 30 manufacturers of this product , and more than 20 companies have been evaluated
.
Parecoxib sodium for injection is the fourth batch of collected varieties, and 10 companies including Qilu Pharmaceutical, Hunan Kelun Pharmaceutical, Jiangsu Osaikang, and Guangzhou Hairui Pharmaceutical of Yangtze River Pharmaceutical Group have won the bid
.
Sales of terminal ambroxol hydrochloride injection in China's public medical institutions in recent years (unit: 100 million yuan) Source: China's public medical institutions terminal competition landscape.
According to data from Mynet, the sales of terminal ambroxol hydrochloride injection in China's public medical institutions in 2020 will exceed 2 billion yuan, Boehringer Ingelheim has the largest market share
.
Up to now, there are 50 manufacturers of this product, and more than 20 companies have been reviewed
.
Ambroxol hydrochloride injection is also the fourth batch of centralized procurement products, and 10 companies including Hubei Kelun Pharmaceutical, Chengdu Better Pharmaceutical, and Sichuan Meidakang Huakang Pharmaceutical have won the bid
.
According to statistics, a total of 46 injections were included in the five batches of national centralized procurement.
Among them, the fifth batch was the largest in history, with 31 injections, accounting for half of all selected varieties, and became the main formulation of centralized procurement.
Compared with the total number of the previous four batches of centralized collection injections, it is more than 2 times
.
At present, there are more than 800 acceptance numbers under review for supplementary applications for consistency evaluation of injections, and more than 600 acceptance numbers for new classification applications under review
.
With the continuous advancement of centralized procurement, the consistency evaluation of injections will continue to accelerate, and the number of over-assessment may continue to increase explosively
.
Source: Minet.
com database If there are any omissions, please correct me!